Patents Issued in December 19, 2019
  • ZIKA AS A CELL PENETRATING PEPTIDE FOR DELIVERY TO THE BRAIN
    Publication number: 20190382451
    Abstract: In various embodiments constructs are provided for the delivery of an effector molecule into a cell. In certain embodiments the construct comprises a cell penetrating peptide (CPP) attached to an effector that is to be delivered into a cell, where the said cell penetrating peptide comprises a Zika cell penetrating peptide (Zika CPP); and the effector is selected from the group consisting of a protein, a nucleic acid, an organic compound, a nanoparticle, a viral particle, and the like.
    Type: Application
    Filed: May 7, 2019
    Publication date: December 19, 2019
    Inventors: Barbara J. Bailus, Lisa M. Ellerby
  • Modified Capsid Proteins for Enhanced Delivery of Parvovirus Vectors
    Publication number: 20190382452
    Abstract: This invention relates to modified parvovirus capsid proteins with enhanced transduction efficiency, viral vectors comprising the same, and methods of using the same for delivery of nucleic acids to a cell or a subject.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 19, 2019
    Inventors: Richard Jude Samulski, Jayme Warischalk
  • Multivalent HIV Vaccine Boost Compositions and Methods of Use
    Publication number: 20190382453
    Abstract: Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521?11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.
    Type: Application
    Filed: February 16, 2017
    Publication date: December 19, 2019
    Inventor: Harriet Robinson
  • A MODIFIED PEPTIDE AS AN ANTICANCER AGENT
    Publication number: 20190382454
    Abstract: A modified peptide AT-01 has been synthesized from the microbiomic secretory protein MPT63 of Mycobacterium tuberculosis. This peptide (about 30 amino acids) contains a portion of the immunogenic region of MPT63 (131 amino acids). It has been found to stabilize SMAR1 (Scaffold Matrix Attachment Region Binding Protein 1), a tumor suppressor protein which is well characterized as anti-cancer. AT-01 was modified further to generate 6 new, independent peptides. Among the peptides AT-01 C and AT-01 D were found to be more effective than the other peptides. AT-01 D also attenuated cell migration of MDA-MB231 cells which supports the anti-metastatic activity. Inhibition of the cell growth from the Colony Formation Assays too supported its anticancer activity. It does not cause toxicity to the cells at high doses which demonstrates great potential value as a safe and effective cancer therapy.
    Type: Application
    Filed: March 7, 2016
    Publication date: December 19, 2019
    Inventors: Samit CHATTOPADHYAY, Nandaraj TAYE, Prabhakar SALUNKHE
  • FUSION MOLECULES
    Publication number: 20190382455
    Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: December 19, 2019
    Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
  • STAPLED PEPTIDE INHIBITORS OF NEMO AS POTENTIAL ANTI-INFLAMMATORY AND ANTI-CANCER DRUGS
    Publication number: 20190382456
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 19, 2019
    Inventors: Fabrice AGOU, Alix BOUCHARLAT, Yves-Marie COIC, Françoise BALEUX
  • Novel Protein With Anti-Inflammatory Properties
    Publication number: 20190382457
    Abstract: The present invention provides an isolated or recombinant protein consisting of the amino acid sequence according to SEQ ID NO: 3 or SEQ ID: NO: 4 and its use in the prevention or treatment of an inflammatory condition.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 19, 2019
    Inventors: Valerie Mary Corrigall, Gabriel Stavros Panayi
  • Multifunctional Heteromultimeric Constructs
    Publication number: 20190382458
    Abstract: The present invention is situated in the field of multimers used for targeted therapies. More particularly, the invention relates to methods for preparing multifunctional heteromultimeric protein complexes with a defined ratio of functional components and to multifunctional heteromultimeric protein complexes for directing complement-dependent cytolysis, optionally comprising a scaffold, which display three or more different functional components present in a defined relative ratio, of which one is a tracking component.
    Type: Application
    Filed: May 22, 2017
    Publication date: December 19, 2019
    Applicants: Luxembourg Institute of Health (LIH), Université de Reims Champagne Ardenne URCA
    Inventors: Xavier Dervillez, Carole Devaux, Jacques H.M. Cohen
  • CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER
    Publication number: 20190382459
    Abstract: Methods of treating a cancer in a patient are provided. The methods can include obtaining a tumor sample from a patient, detecting whether CCNG1 gene expression is present in the tumor sample, diagnosing the patient with a CCNG1 inhibitor-responsive cancer when the presence of CCNG1 gene expression in the tumor sample is detected, and/or administering an effective amount of a CCNG1 inhibitor to the diagnosed patient. CCNG1 inhibitors can include a viral vector having a binding peptide that is configured to bind one or more signature (SIG) elements of an invading tumor and at least one cytocidal gene. CCNG1 inhibitors including cell penetrating peptides are also provided.
    Type: Application
    Filed: February 2, 2018
    Publication date: December 19, 2019
    Inventors: Erlinda M. Gordon, Frederick L. Hall
  • Modified FGF-21 Polypeptides and Uses Thereof
    Publication number: 20190382460
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 19, 2019
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • FUSION POLYPEPTIDES AND METHODS OF USE
    Publication number: 20190382461
    Abstract: Disclosed are fusion polypeptides comprising fragments from a first and a second isoform of an interferon lambda family, nucleic acids encoding the fusion polypeptides, and vectors and host cells containing the same, and methods of making and using such compositions in treatment of interferon lambda-related diseases, disorders, and conditions.
    Type: Application
    Filed: January 18, 2019
    Publication date: December 19, 2019
    Inventors: Hongyu Liu, Mingzhi Zhao, Hetong Sun
  • METHODS AND COMPOSITIONS FOR TREATING HPA HYPERACTIVITY
    Publication number: 20190382462
    Abstract: Disclosed are engineered corticotropin-releasing factor (CRF) antagonist agents, including engineered corticotropin-releasing factor (CRF) binding agents. The CRF antagonist agents and binding agents can be used to neutralize excess CRF in vivo and comprise a polypeptide having CRF-specific binding activity under physiological conditions coupled to one or more half-life-extending moieties. Pharmaceutical compositions are disclosed containing the CRF binding agents, which can be used in methods of treatment for diseases, disorders, or conditions involving hypothalamic pituitary adrenal (HPA) axis hyperactivity. Also disclosed are engineered nucleic acids (e.g., expression constructs or vectors) encoding the CRF binding agents and recombinant host cells comprising the engineered nucleic acids.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 19, 2019
    Inventors: Pietro P. SANNA, Linda S. LLOYD
  • NON-STANDARD INSULIN ANALOGUES
    Publication number: 20190382463
    Abstract: An insulin analogue comprises an insulin A-chain polypeptide and an insulin B-chain polypeptide. The A-chain polypeptide contains a Glu substitution at a position corresponding to position A8, and an Ala, Glu, Gln, His, Tyr, Phe or Trp substitution at a position A13, relative to wild type insulin. The B-chain polypeptide contains a cyclohexanylalanine substitution at position B24, relative to wild type insulin. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.
    Type: Application
    Filed: July 26, 2019
    Publication date: December 19, 2019
    Inventor: Michael A. WEISS
  • PHARMACEUTICAL COMPOSITION OR FOOD COMPOSITION, AND METHOD FOR ASSESSING EFFECT OF ACTIVE INGREDIENT IN VIVO
    Publication number: 20190382464
    Abstract: An object of the present invention is to provide a pharmaceutical composition or food or drink composition comprising an active ingredient that suppresses functional expression of Oscar protein. Another object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating kidney disease A further object of the present invention is to provide a pharmaceutical composition or food or drink composition that suppresses functional expression of Oscar in a living organism in order to suppress functional expression of FGF23. A still further object of the present invention is to provide a method for evaluating an effect, in the body, of an active ingredient that suppresses functional expression of Oscar protein.
    Type: Application
    Filed: March 29, 2017
    Publication date: December 19, 2019
    Applicant: ADVANCED TELECOMMUNICATIONS RESEARCH INSTITUTE INTERNATIONAL
    Inventor: Narutoku SATO
  • Fusion Polypeptides Capable Of Activating Receptors
    Publication number: 20190382465
    Abstract: A fusion polypeptide comprising (A)x-M-A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
    Type: Application
    Filed: August 6, 2019
    Publication date: December 19, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
  • CSF1R-BASED CHIMERIC PROTEINS
    Publication number: 20190382466
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 19, 2019
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS
    Publication number: 20190382467
    Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
    Type: Application
    Filed: March 20, 2019
    Publication date: December 19, 2019
    Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20190382468
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 19, 2019
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • RAPID METHOD FOR CLONING AND EXPRESSION OF COGNATE ANTIBODY VARIABLE GENE SEGMENTS
    Publication number: 20190382469
    Abstract: In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed E. coli cells.
    Type: Application
    Filed: January 10, 2019
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Simone Hoege, Erhard Kopetzki, Dominique Ostler, Stefan Seeber, Georg Tiefenthaler
  • SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
    Publication number: 20190382470
    Abstract: Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
    Type: Application
    Filed: April 16, 2019
    Publication date: December 19, 2019
    Inventors: Gottfried Himmler, Florian Ruker, Gordana Wozniak-Knopp
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20190382471
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Application
    Filed: June 23, 2017
    Publication date: December 19, 2019
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • ANTI-C5 ANTIBODIES AND METHODS OF TREATING COMPLEMENT-RELATED DISEASES
    Publication number: 20190382472
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 19, 2019
    Applicant: Seoul National University R&DB Foundation
    Inventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20190382473
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO
  • ANTI-IL-27 ANTIBODIES AND USES THEREOF
    Publication number: 20190382474
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Application
    Filed: March 22, 2019
    Publication date: December 19, 2019
    Inventors: Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY
  • ENGINEERED HETERODIMERIC PROTEINS
    Publication number: 20190382475
    Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.
    Type: Application
    Filed: March 1, 2018
    Publication date: December 19, 2019
    Inventors: Regis CEBE, Sebastien IRIGARAY, Darko SKEGRO
  • USE OF TETRASPANIN-2 FOR TREATING DIABETES AND SCREENING AN ANTI-DIABETIC AGENT
    Publication number: 20190382476
    Abstract: There is provided a method for treating diabetes in a subject in need thereof, the method comprising administering to the subject a composition comprising a tetraspanin-2 (TSPAN2) protein activity inhibitor as an active ingredient in an amount effective for treating diabetes
    Type: Application
    Filed: May 29, 2019
    Publication date: December 19, 2019
    Inventors: Ik Soon Jang, Kyung Bok Lee, Hyun Jin Jang
  • ANTI-PVRIG/ANTI-TIGIT BISPECIFIC ANTIBODIES AND METHODS OF USE
    Publication number: 20190382477
    Abstract: Anti-PVRIG, anti-TIGIT, and anti-PVRIG/anti-TIGIT bispecific antibodies are provided, as well as compositions, and methods of using the antibodies for the treatment of cancer.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 19, 2019
    Inventors: Andrew W. Drake, Sandeep Kumar, Sayantan Mitra, Adam Sallers, Sarah Whelan, Arun Kashyap, Keith Akama, Neha Yevaekar
  • Nucleolin Antibodies
    Publication number: 20190382478
    Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.
    Type: Application
    Filed: June 27, 2019
    Publication date: December 19, 2019
    Inventors: Natalie Sutkowski, Daniel Fernandes, Brian Hoel, Semyon Rubinchik
  • ERYTHROCYTE-BINDING THERAPEUTICS
    Publication number: 20190382479
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Application
    Filed: July 26, 2019
    Publication date: December 19, 2019
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • ANTI-TIM3 ANTIBODIES AND METHODS OF USE
    Publication number: 20190382480
    Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.
    Type: Application
    Filed: February 6, 2019
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
  • ANTI-CD33 ANTIBODIES, ANTI-CD33/ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20190382481
    Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Application
    Filed: May 21, 2019
    Publication date: December 19, 2019
    Inventors: Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta
  • ANTIGEN BINDING PROTEINS
    Publication number: 20190382482
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 19, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • NEW USES OF ANTI-SIRPg ANTIBODIES
    Publication number: 20190382483
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.
    Type: Application
    Filed: February 15, 2018
    Publication date: December 19, 2019
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VANESSA GAUTTIER, Virginie THEPENIER, Sabrina PENGAM, BERNARD VANHOVE
  • PHARMACEUTICAL COMPOSITION, ANTIGEN-BINDING MOLECULES, TREATMENT METHOD, AND SCREENING METHOD
    Publication number: 20190382484
    Abstract: The present invention relates to pharmaceutical compositions containing a combination of a first antigen-binding molecule and a second antigen-binding molecule, wherein the first antigen-binding molecule and the second antigen-binding molecule are not linked by a covalent bond, and they are more likely to form a heterodimer than homodimers when mixed in solution. Furthermore, the present invention relates to antigen-binding molecules, therapeutic methods, and screening methods that are associated with the combination.
    Type: Application
    Filed: February 23, 2018
    Publication date: December 19, 2019
    Inventors: Tomoyuki IGAWA, Hitoshi KATADA, Takeaki KAWAI
  • T CELL RECRUITING POLYPEPTIDES BASED ON CD3 REACTIVITY
    Publication number: 20190382485
    Abstract: T cell recruiting polypeptides are provided that bind CD3 on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Application
    Filed: May 13, 2016
    Publication date: December 19, 2019
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • ANTIBODIES SPECIFIC FOR CD3 AND USES THEREOF
    Publication number: 20190382486
    Abstract: The present invention provides novel antibodies that specifically bind to CD3 and uses thereof. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: May 21, 2019
    Publication date: December 19, 2019
    Applicant: Pfizer Inc.
    Inventors: James Reasoner Apgar, Fang Jin, Madan Katragadda, Divya Mathur, Lioudmila Gennadievna Tchistiakova
  • ANTIGEN BINDING CONSTRUCTS TO CD8
    Publication number: 20190382487
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: May 20, 2019
    Publication date: December 19, 2019
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • ANTIGEN BINDING CONSTRUCTS TO CD8
    Publication number: 20190382488
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: May 20, 2019
    Publication date: December 19, 2019
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190382489
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE
    Publication number: 20190382490
    Abstract: The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 19, 2019
    Inventors: John T. LOFFREDO, Katherine E. LEWIS, Robert F. GRAZIANO, Alan J. KORMAN
  • TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANTI-CD137
    Publication number: 20190382491
    Abstract: This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD 137.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 19, 2019
    Inventors: Maria Jure-Kunkel, David M. Berman, Alan J. Korman, Mark J. Selby, Suba Krishnan
  • DRUG DELIVERY COMPOSITIONS AND USES THEREOF
    Publication number: 20190382492
    Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.
    Type: Application
    Filed: August 26, 2019
    Publication date: December 19, 2019
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Michael Solomon Goldberg, Chun Gwon Park
  • ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190382493
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 19, 2019
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T.L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
    Publication number: 20190382494
    Abstract: Provided herein are compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-L1 antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided.
    Type: Application
    Filed: August 28, 2019
    Publication date: December 19, 2019
    Inventors: JIALI DU, AMBARISH SHAH
  • BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
    Publication number: 20190382495
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 19, 2019
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
  • ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF
    Publication number: 20190382496
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Application
    Filed: March 27, 2018
    Publication date: December 19, 2019
    Inventors: Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS
  • Antibodies Directed Against CD127
    Publication number: 20190382497
    Abstract: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 19, 2019
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE
  • HUMANIZED IMMUNOBINDERS OF CELL-SURFACE ANTIGENS
    Publication number: 20190382498
    Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 19, 2019
    Inventors: David Urech, Valerie Hulmann-Cottier, Leonardo Borras
  • PRION PROTEIN ANTIBODIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20190382499
    Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.
    Type: Application
    Filed: April 30, 2019
    Publication date: December 19, 2019
    Inventors: John Collinge, Andrew J. Nicoll
  • BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20190382500
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 19, 2019
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang